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Abstract. The aim of the present study was to investigate the 
effects of three different formulations of hyaluronic acid (HA): 
Low molecular weight (MW) Sinovial One®, medium MW 
Viscoplus® and high MW Durolane®, on chondrocyte prolif-
eration and collagen type II (COL2A1), hypoxia-inducible 
factor 1α (HIF-1α) and chondroadherin (CHAD) expression in 
primary chondrocyte cultures. Standard primary chondrocyte 
cultures were established from osteochondral tissues surgically 
obtained from 6 patients with gonarthrosis. Cell morphology 
was evaluated using an inverted light microscope; cell prolif-
eration was determined with a MTT assay and confirmed with 
acridine orange/propidium iodide staining. Levels of CHAD, 
COL2A1 and HIF-1α expression were assessed using specific 
TaqMan gene expression assays. The results demonstrated the 
positive effect of HA treatment on cell proliferation, which 
was independent from the MW. COL2A1 expression increased 
in the medium and high MW HA treated groups. It was 
observed that HIF-1α expression increased in the high MW 
treated group alone. CHAD expression increased only in the 
medium MW HA treated group. Evaluation of gene expression 
revealed that levels of expression increased as the duration of 
HA application increased, in the medium and high MW HA 
treated groups. In terms of increased viability and prolifera-
tion, a longer duration of HA application was more effective. 
Taken together, it may be concluded that the administration 
of medium and high MW HA may be a successful way of 
treating diseases affecting chondrocytes in a clinical setting.
Introduction
Osteoarthritis (OA) is the most common form of arthritis 
and a major cause of reduced activity and disability, with 
an increased incidence after 65 years of age, which is char-
acterized by progressive cartilage degradation (1-3). The 
primary aims of treatments for OA are to reduce the pain and 
disability experienced by patients, thus improving quality of 
life. Various medications, including analgesics, non-steroidal 
anti‑inflammatories, platelet‑rich plasma and steroids, are used 
in combination with physical therapy and/or surgery to treat 
those with OA (4). However, novel treatments to prevent chon-
drocyte degeneration are required, as current treatments only 
alleviate symptoms of OA and do not tackle the underlying 
causes of the disease (5). In addition to analgesics, non-steroidal 
anti-inflammatories, platelet-rich plasma and steroids, 
intra-articular injections of hyaluronic acid (HA), a slow-acting 
chondroprotective agent, are frequently administered to 
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patients with OA (5,6). HA has a more prolonged effect and 
avoids several of the side effects associated with conventional 
OA treatment, including gastrointestinal toxicity or increased 
risk of the cardiovascular events (4,7,8).
HA is a long chain polysaccharide present in loose 
connective tissue, skin, the eyes and synovial fluid (4,7,9). HA 
is concentrated at the surface of the articular cartilage and 
the superficial layers of the synovial membrane and forms 
a semi-permeable barrier between the synovial fluid and 
cartilage. Marked decreases in HA concentration is associ-
ated with the onset of OA (4,7). In pathological conditions, 
the molecular weight (MW) of HA also decreases, which 
increases the cartilage mechanical load, thus inducing damage 
of the cartilage (1,9). The administration of HA was previously 
determined to reduce chondrocyte apoptosis rate in patients 
with OA (10). The role of HA in OA remains unclear; however, 
it may promote cell proliferation and pericellular matrix 
formation (4,7,11).
In the present study, the effect of different MWs of HA 
on the proliferation of chondrocytes, as well as the expression 
of collagen type II (COL2A1), hypoxia-inducible factor 1α 
(HIF-1α) and chondroadherin (CHAD) in chondrocytes was 
investigated. To the best of our knowledge, the current study 
is the first to determine the effects of HA on the expression 
of HIF-1 and CHAD. Impairment of anabolic and catabolic 
processes is common features of OA. In healthy cartilage, 
the presence of COL2A1 is a marker of anabolism (5). The 
COL2A1 gene encodes an important cartilage‑specific matrix 
protein and its expression is regulated by transcription factors, 
including SOX9 and transforming growth factor ß (12). 
Furthermore, it has been demonstrated that an increase in 
COL2A1 expression induces the production of extracellular 
matrix (ECM) (12).
HIF-1 regulates the transcription of a wide range of 
genes involved in glucose metabolism, angiogenesis and cell 
survival (2,3). The HIF-1 heterodimeric transcription complex 
is composed of HIF-1α and HIF-1β subunits. A hypoxic 
environment, hormones and growth factors can induce the 
translocation of HIF-1 to the nucleus, where it associates with 
its corresponding subunit to form an active HIF-1 transcription 
factor that may regulate the expression of its target genes (2,3). 
HIF-1α regulates hypoxia-induced ECM synthesis in chondro-
cytes, as well as cartilage regeneration (13-15).
CHAD is a class IV small leucine-rich proteoglycan/protein 
that mediates the signaling between chondrocytes and the 
ECM (16). CHAD binds to the α2β1 integrin, cell surface 
proteoglycans and type II collagen and serves a role in the regu-
lation of chondrocyte signaling and cartilage homeostasis (16).
The present study investigated the effect of treatment with 
low, medium and high MW HA on COL2A1, HIF-1α and 
CHAD expression in chondrocytes. Furthermore, the effect of 
HA on chondrocyte viability and proliferation was assessed. 
The aim of the current study was to determine whether the 
administration of different MWs of HA may be an effective 
method of treating patients with OA in a clinical setting.
Materials and methods
Patient selection. Cartilage tissue was obtained from 
14 patients diagnosed with OA from Istanbul Medipol 
University Hospital, Namik Kemal University Hospital, 
Gaziosmanpasa Taksim Training and Research Hospital, 
Abant Izzet Baysal University Hospital, Istanbul Medipol 
University Hospital, Pamukkale University Hospital, Medical 
Park Hospital, Denizli Private Hospital and Memorial Hospital. 
Osteophytes were graded using the Kellgren-Lawrence radio-
logical grading scale (17). Patients were excluded if they had 
defects in kidney function or an allergy to a specific protein, 
including milk, egg or avian, or if they had taken metho-
trexate, fludarabine, cyclophosphamide, high doses of steroid 
and/or pressor substances, monoamine oxidase, coumarin 
group anticoagulants, phenytoin, primidone, phenylbutazone 
or tricyclic antidepressants in the preceding year. A total of 
6 patients (3 female and 3 male; mean age, 64.92±3.68 years) 
were included in the current study. These patients were also 
unresponsive to medical and conservative treatments for 
gonarthrosis. The present study was performed with the 
approval of the Local Ethics Board of Pamukkale University 
(Denizli, Turkey). Informed consent was obtained from 
patients attending the Orthopedics and Traumatology Clinic 
of all the aforementioned hospitals between August 2016 and 
June 2017, for use of their cells. Researchers did not know 
which groups received drugs and were blinded to which drugs 
were applied to the culture.
Study design and in vitro experimental setup. Standard primary 
chondrocyte cultures were established from surgically obtained 
osteochondral tissues taken from all 6 patients. Chondrocyte 
cultures were monitored using an inverted microscope. HAs 
of different MWs has been prepared using the appropriate 
solutions and concentrations. In the well plates, color-coded 
HAs were added and an extra plate from each treatment was 
set aside for MTT analysis, acridin orange/propidium iodide 
(AO/PI) staining and reverse transcription-quantitative poly-
merase chain reaction (RT-qPCR).
Isolation of primary chondrocytes. Osteochondral tissues 
were obtained from the distal femur and proximal tibia in 
patients with OA undergoing total knee arthroplasty for gonar-
throsis. Tissues were transferred to the laboratory and cultured 
at 37˚C in Dulbecco's modified Eagle's medium supplemented 
with 1% penicillin-streptomycin, 15% fetal bovine serum and 
1% L‑glutamine (all Gibco; Thermo Fisher Scientific, Inc., 
Waltham, MA, USA). Osteochondral tissue samples were irri-
gated with 0.9% isotonic sodium chloride solution in a laminar 
flow cabinet to isolate samples from red blood cells. Tissues 
were dissected into 0.4 cm3 pieces, washed in Hank's balanced 
salt solution (Gibco; Thermo Fisher Scientific, Inc.) and trans-
ferred to Falcon tubes. Collagenase type II (0.375 mg; Gibco; 
Thermo Fisher Scientific, Inc.) dissolved in complete medium 
was added and incubated with tissues at 37˚C overnight in 5% 
CO2. Samples were then centrifuged at a speed of 130 x g for 
10 min in a coolant centrifuge at 4˚C. Cells were subsequently 
re‑suspended in culture medium and transferred to T75 flasks 
prior to incubation at 37˚C with 5% CO2 to obtain primary 
cell cultures. The cultures were incubated until they became 
a monolayer confluent culture. Incubation duration differs 
between samples depending on the age of the patient, viable 
cell count, transport conditions and to doubling times of cells 
where they originated from, as previously described (18).
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Monolayer primary chondrocyte cultures were trypsinized 
and viable cells were identified via staining with trypan blue. 
Cell suspensions were seeded at a density of 1x104 cells/well 
in 96-well plates for MTT analysis, 3x104 cells/well in 24-well 
plates for AO/PI analysis and 4x106 cell/dish in 100-mm 
petri dishes for RNA isolation. Following 24 h incubation at 
37˚C, low, medium and high MW HA was added to these cell 
cultures (0 h). Results from each experiment were obtained at 
0, 24 and 48 h following HA treatment.
Preparation and application of HA. The stock solution 
concentrations of the HA preparations used were: Low 
MW (800-1,200 kDa; Sinovial One®; 50 mg/2.5 ml; IBSA 
Farmaceutici, Lodi, Italia), medium MW (2,500 kDa; 
Viscoplus®; 75 mg/3 ml; BioMedical B. Baumann GmbH, 
Rodgau, Germany) and high MW HA (10,000 kDa; Durolane®; 
60 mg/ml; Bioventus LCC, Durham, NC, USA). A HA concen-
tration of 1 µM was used in all experiments, as the majority of 
pharmaceutical formulations are administered at this concen-
tration (19).
AO/PI staining. The AO/PI staining solution consisted of 10 g 
disodium-EDTA, 4 mg PI, 50 ml FBS and 4 mg AO (dissolved 
in 2 ml 99% ethanol). The solution was mixed well and sterile 
distilled water was added to form a final volume of 200 ml. 
After incubation for 10 min at room temperature, cell cultures 
were monitored using a fluorescent microscope.
The nucleic acid binding dyes AO and PI may be used to 
accurately determine cell viability. AO is an intercalating dye 
able to permeate living and dead cells; it stains all nucleated 
cells and generates green fluorescence. PI can only enter dead 
cells with poor membrane integrity; it stains all dead nucleated 
cells to generate red fluorescence. Following staining with 
AO/PI, live nucleated cells exhibit green fluorescence and all 
dead nucleated cells exhibit red fluorescence (20).
Imaging with inverted and fluorescence microscopy. An 
inverted light microscope (magnification, x20; CKX41; 
Olympus Corporation, Tokyo, Japan) was used to monitor cell 
cultures and a fluorescent microscope (magnification, x20; 
DM2500; Leica Microsystems, Inc., Buffalo Grove, IL, USA) 
was used for analysis of AO/PI staining. Microphotographs of 
the cell organizations were obtained prior to and during HA 
treatment and images were evaluated using the CytoVision 
capture station imaging program V.7.2 (Leica Microsystems, 
Inc.).
MTT analysis. Cell viability was assessed using a commercial 
MTT kit (Vybrant® MTT cell proliferation assay kit; Thermo 
Fisher Scientific, Inc.) following the manufacturer's protocol. 
MTT was prepared by adding 1 ml sterile PBS to a vial 
containing 5 mg MTT to obtain a 12 mM MTT stock solution. 
To analyze cell viability, 10% MTT solution prepared with 
complete medium was applied to monolayer cultures. Cultures 
were then incubated in a dark environment at 37˚C for 4 h. 
At the end of the incubation period, dimethyl sulfoxide was 
added to dissolve the purple formazan and incubated at 37˚C 
for an additional 10 min. Absorbance was then measured at 
a wavelength of 540 nm. MTT analysis was performed prior 
to the addition of HA (0 h; control) as well as 24 and 48 h 
following HA addition (18,20-25). Absorbance was measured 
using a microplate reader (Mindray MR-96A; Shenzhen 
Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China).
Gene‑specific RT‑qPCR analysis. Total RNA was extracted 
from cultured primary human chondrocytes using the PureLink 
RNA mini kit (cat. no. 12183018A; Ambion; Thermo Fisher 
Scientific, Inc.) and 2-mercaptoethanol (cat. no. 31350010; 
Thermo Fisher Scientific, Inc.). The quantity of RNA obtained 
from each sample was measured using a UV spectrophotometer 
(UV-VIS Spectrophotometer 2600; Shimadzu Corporation, 
Kyoto, Japan). To obtain cDNA, 50 ng RNA was reverse tran-
scribed using a high-capacity cDNA reverse transcription kit 
(cat. no. 4368814; Thermo Fisher Scientific, Inc.) and a thermal 
cycler (ProFlex; Thermo Fisher Scientific, Inc.). For RT, 10 µl 
10X reverse transcription buffer, 4 µl 25X dNTP, 10 µl 10X 
random primers, 5 µl 50 U/µl reverse transcriptase, 51 µl 
nuclease free water and 20 µl RNA were mixed well and held 
at 25˚C for 10 min, and then maintained at 37˚C for 2 h. All 
genes were amplified using TaqMan® Gene Expression assays 
for CHAD (assay ID. Hs00154382_m1; cat. no. 4448892), 
HIF-1α (assay ID. Hs00153153_m1; cat. no. 4453320), COL2A1 
(assay ID. Hs00264051_m1; cat. no. 4453320) and internal 
control gene [housekeeping genes-actin beta (ACTB; assay 
ID. Hs99999903_m1; cat. no. 4453320)]. qPCR was performed 
on an Applied Biosystems 7300/7500 real-time PCR system 
(Thermo Fisher Scientific, Inc.) and the reaction mixture 
consisted of 1 µl TaqMan gene expression assay, 10 µl TaqMan 
gene expression master mix (cat. no. 4369016), 4 µl cDNA 
template and UltraPure DNase/RNase-free distilled water 
(cat. no. 10977035) for each gene in MicroAmp fast optical 
96-well reaction plates (cat. no. 4346906). The thermocycling 
conditions were as follows: 2 min at 50˚C, 10 min at 95˚C, 
15 sec at 95˚C and 1 min at 60˚C, for 40 cycles. As a result of 
the RT-qPCR experiment, the RQ values of each sample were 
obtained using the 7500 Fast-SDS program V.2.3 (Thermo 
Fisher Scientific, Inc.). An endogenous control (ACTB) was 
utilized to normalize the target gene expression. For compara-
tive results, a reference (calibrator) sample (Group 1, 0 h) was 
used and relative quantity (RQ) values were calculated using 
the 2-ΔΔCq method (21).
Statistical analysis. Statistical analysis was performed using 
the Minitab program (version 16; Minitab, Inc., State College, 
PA, USA). All data are expressed as the mean ± standard 
deviation. The results were evaluated using repeated measures 
one-way analysis of variance to assess whether there were 
significant differences across experimental groups, followed 
by Tukey's honest significant difference test for post hoc 
analysis. P<0.05 was considered to indicate a statistically 
significant difference. All experiments were repeated at least 
three times. To avoid measurement errors, the same types of 
analysis were performed by the same researchers.
Results
Morphological evaluation of chondrocyte cultures. Chondrocyte 
morphology was evaluated 24 and 48 h following treatment with 
low, medium and high MW HA. Cell proliferation in the control 
group at 24 h was greater than in all HA-treated experimental 
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groups. Although the number of cells appeared fewer in number 
than HA-treated groups in morphological observations, MTT 
analysis demonstrated that the viable cell ratio remained almost 
the same at 24 h in all groups. However, it was observed that 
chondrocyte proliferation increased in all experimental groups 
at 48 h following HA treatment, particularly in the high-MW 
HA treatment group that underwent morphological evalua-
tion (Fig. 1). Despite cultures in HA-treated groups having a 
weaker confluency following 24 h, to demonstrate that HA or 
its components do not suppress chondrocyte proliferation and to 
confirm MTT data cell viability in the same cultures were also 
assessed using AO/PI staining. Micrographs obtained following 
AO/PI staining are presented in Fig. 2. Cells retained their 
specific morphology, maintained viability and continued to 
proliferate in all experimental groups according to microscopic 
examinations, indicating that HA does not have a repressive 
effect (Fig. 2).
Statistical analysis of chondrocyte proliferation. Cell viability 
was determined by MTT analysis, confirmed by AO/PI 
staining and evaluated statistically. The results revealed that 
the increase in cell proliferation was significantly associated 
with the duration of application (P<0.05; Fig. 3). However, 
there were no significant differences between the cell viability 
in the groups treated with HA that had different MWs (Table I).
Analysis of CHAD, COL2A1 and HIF‑1α gene expression. The 
expression of CHAD, COL2A1 and HIF‑1α were assessed 24 
and 48 h following treatment with HA at different MWs. RQ) 
values were calculated for each experimental group using the 
7500 Fast-SDS program. β-actin was used as endogenous 
Figure 1. Inverted microscopy images of primary chondrocyte cultures 
(magnification, x20). MW, molecular weight; HA, hyaluronic acid.
Figure 2. AO/PI staining of chondrocyte cultures. Cells stained green indicate 
viable chondrocytes. Cells with red nuclei indicate cell death or degenerated 
membrane integrity (magnification, 20x). MW, molecular weight; HA, hyal-
uronic acid; AO, acridine orange; PI, propidium iodide.
Figure 3. Statistical analyses; pairwise comparisons for MTT analysis 
assessing cell proliferation. Increased cell viability was statistically signifi-
cant (*P<0.005) in all experimental groups (low, medium and high MW HA) 
when compared to control group at 48 h.
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control and the control group at 0 h was designated to be the 
reference sample. The expression of the gene of interest was 
determined as 100% and the RQ value was 1 in the reference 
sample and RQ values of other samples were calculated as fold 
changes with comparison to this reference (21). No further 
statistical analysis was performed on the obtained RQ values.
Fig. 4 summarizes the RQ values determined for each 
experimental group. In the medium MW HA treated group, 
COL2A1 gene expression increased 1.73-fold and CHAD 
gene expression increased 1.35-fold at 48 h compared with the 
control group. Furthermore, at 24 h, the COL2A1 gene RQ 
value was 1.05. In the high MW HA treated group, the RQ 
value determined for the COL2A1 gene was 1.06 at 24 h and 
RQ value determined for the HIF-1α gene was 1.07 at 48 h 
(Fig. 4).
Discussion
The primary goal of treatments for cartilage damage is to 
completely restore hyaline cartilage. Surgery and other treat-
ments are being developed for this purpose. Although there 
are a number of promising methods and some encouraging 
clinical results, no treatments have achieved complete restora-
tion (1,4). Viscosupplementation with HA is an example of a 
promising treatment method. HA injections reduce pain and 
recover joint function by functioning as a lubricant and shock 
absorber (4,6). Although not fully understood, HA injections 
have been demonstrated to inhibit inflammation, decrease 
cartilage degradation and induce ECM synthesis (1,6). 
Surgeons cannot yet achieve biological repair following carti-
lage damage; however, treatment with HA is preferred as it 
inhibits the pathophysiological pathway leading to arthrosis 
and reduces the pain and movement limitation experienced by 
patients (1).
HA concentrations are decreased in the affected joints of 
patients with OA. It has been suggested that HA treatment is 
more beneficial than viscous fluid replacement therapy, as it 
stimulates tissue organization and modulates inflammation and 
macrophages (8,19). Consequently, various commercial HA 
preparations with different MWs are clinically used (9,23-25). 
Certain studies have indicated that high MW HA is more 
effective than low MW HA in treating OA; however, other 
studies suggest that there is no substantial evidence to support 
this (1,24-27). In the present study, chondrocyte cultures were 
Table I. Statistical analysis of hyaluronic acid application with one‑way analysis of variance and Tukey's post hoc test.
 Mean OD ± SD
Hyaluronic acid -----------------------------------------------------------------------------------------------------------------------------------
treatment 0 h 24 h 48 h P-value
Low MW 0.322±0.03 0.328±0.05 0.310±0.01 0.310
Medium MW 0.322±0.03 0.332±0.04 0.334±0.01 0.311
High MW 0.322±0.03 0.320±0.06 0.332±0.03 0.298
Control 0.322±0.03 0.317±0.06 0.249±0.01 0.296
Results are presented as the mean ± standard deviation. MW, molecular weight, OD, optical density, SD, standard deviation. There were no 
significant differences between the cell viability in the groups treated with HA that had different MWs.
Figure 4. RQ values obtained for chondroadherin, collagen type II α chain 1 and hypoxia-inducible factor 1α expression. HA, hyaluronic acid; MW, molecular 
weight; RQ, relative quantity.
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morphologically evaluated and cell viability and proliferation 
were determined. The results revealed that the positive effect 
of HA treatment on cell proliferation was independent of the 
MW of HA.
Animal tissue or commercial cell lines were not used in 
the current study; instead, cartilage tissues were obtained 
from patients with knee prosthesis during the course of routine 
clinical practice. Following knee prosthesis, undamaged 
chondral tissues of the resectioned articular surface were used 
to prepare primary chondrocyte cultures. Human primary 
articular chondrocyte cultures model complete tissue as they 
contain all cell types and ECM components of their original 
tissue (28-31); therefore the results of the present study may 
enhance understanding of how cartilage degeneration occurs. 
However, as the effects of HA in the present study were only 
evaluated in vitro, the results cannot be generalized to predict 
the effects of HA in vivo.
In the present study, the effect of HA with different MWs 
on the levels of COL2A1, HIF-1α and CHAD expression 
was investigated. The COL2A1 gene encodes an important 
cartilage‑specific extracellular matrix protein that is synthe-
sized from proliferative chondrocytes and is essential for 
chondrogenesis (12,32). In the developing cartilage of the 
growing bone, chondrocytes alter their morphology to become 
hypertrophic and do not express COL2A1. In adult articular 
cartilage, hypertrophic differentiation processes do not occur 
and COL2A1 is expressed (32). However, in OA degenerative 
articular cartilage, phenotypic conversion to hypertrophic 
chondrocytes has been reported (32). Furthermore, anabolic 
and catabolic processes are broadly affected in OA (12) and 
in cartilage, COL2A1 expression is a marker of anabolic 
processes (5). A previous study revealed that COL2A1 
expression increases when chondrocytes are cultured with 
HA and growth factors (12). It has also been reported that 
COL2A1 expression increases in human OA-derived chon-
drocytes following treatment with high MW HA (5). The 
results of the present study demonstrated that COL2A1 
gene expression increased in chondrocytes following treat-
ment with medium and high MW HA. COL2A1 expression 
was 5.58-fold higher in the medium MW HA treated group 
(RQ=1.05) compared with the control group (RQ=0.18) at 
24 h. Furthermore, COL2A1 expression was 1.8-fold higher 
in the medium MW HA treated group (RQ=1.73) compared 
with the control group (RQ=0.96) at 48 h. A 5.88-fold increase 
in COL2A1 expression was only observed (RQ=1.06) in the 
high MW HA treated group at 24 h. However, COL2A1 
expression was the same as the control following 48 h. It was 
also demonstrated that increased duration of medium MW 
HA treatment increased the expression of the COL2A1 gene, 
which is associated with chondrocyte proliferation and ECM 
formation.
Chondrogenesis is regulated by numerous mechanisms, 
including growth factors, cytokines and oxygen supply (15). 
During the initial stages of chondrogenesis, the developing 
cartilaginous template is avascularized and forms hypoxic 
niches (13,15). HIF-1α is a basic helix-loop-helix transcrip-
tion factor expressed in hypoxic conditions (13,14). HIF-1 
is a heterodimer of α and β subunits. The expression of 
the α subunit is induced by hypoxia, whereas the β subunit 
is constitutively expressed in the nucleus. In hypoxic 
conditions, the activity of the HIF-targeting prolyl hydroxy-
lase enzymes (PHD)1, PHD2 and PHD3 is inactivated; 
as a result, HIF-1α, is not hydroxylated and accumulates 
in the cytoplasm. Following this, HIF-1 translocates into 
the nucleus and dimerizes with HIF-1β to form the HIF-1 
complex. This complex subsequently binds to hypoxia 
responsive elements within the promoter region of target 
genes, including Sox9, vascular endothelial growth factor A, 
glycolytic enzymes and glucose transporters, and induces 
their transcription, stimulating chondrocyte differentiation 
and hypoxic condition adaptation (13,15). HIF-1 therefore 
positively regulates cartilage development and regenera-
tion (13,14). Several studies have suggested that HIF-1α 
serves a role in regulating hypoxia-induced ECM synthesis 
in chondrocytes (13-15). In the present study, it was observed 
that HIF-1α expression (RQ=1.07) was 1.53-fold higher than 
the control group (RQ=0.70) at 48 h in the high MW HA 
group only.
CHAD is a non-canonical class IV small leucine-rich 
proteoglycan/protein. This 38 kDa protein mediates signaling 
between chondrocytes and the ECM via α2β1 integrin, cell 
surface proteoglycans and type II collagen binding (16). 
It has been demonstrated that the expression of CHAD is 
upregulated in chondrocyte cultures (33). CHAD predomi-
nantly regulates the formation of the collagen fibrillar 
network during early skeletal development. Therefore, it 
has been hypothesized that CHAD downregulation serves a 
critical role in the initiation and progression of OA (16). In 
the present study, a 1.49-fold increase in CHAD expression 
(RQ=1.36) following 48 h was observed in the medium MW 
group alone.
The present study was performed in in vitro primary 
cultures that directly reflected the entire structure of the orig-
inal tissue, increasing the value of the obtained data. However, 
these primary cultures were established using samples taken 
from only 6 patients; therefore, further studies are required 
to definitively establish the effect of different MWs of HA on 
the expression of different genes in OA. OA is a multifacto-
rial disease; therefore gene expression in different patients 
may vary due to individual differences, independent from 
disease (34). In the present study, gene expression increased 
as the duration of treatment increased in the medium and high 
MW groups. Furthermore, the increased duration of treat-
ment increased chondrocyte viability and proliferation. Taken 
together, these results indicate that administration of medium 
and high MW HA may be successful at treating patients with 
OA.
In conclusion, the present study evaluated the effects 
of low, medium and high MW HA on the expression of 
COL2A1, CHAD and HIF-1α in a robust in vitro culture of 
human-derived chondrocytes. Similar to previous studies, 
an increase in COL2A1, CHAD and HIF-1α expression and 
proliferation was observed, particularly in cultures treated with 
medium and high MW HA. Further studies are required to 
confirm these results in vivo. Typically, it is difficult to imitate 
the full scope of OA with all the involved cellular constitu-
ents in vitro. Therefore, the majority of in vitro OA models 
are designed to focus on the late stages of disease, or use cell 
lines. However, this has significant limitations and it is critical 
to evaluate the mechanisms that are affected during the early 
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stages of OA and in primary cell cultures. The present study 
demonstrated that HA administration at different molecular 
weights to cell cultures, over short periods (24 and 48 h) 
changed the expression of certain genes. Further study into 
gene expression is required to define treatment protocols and 
elucidate the pathogenesis of OA. However, clinicians should 
consider the cellular effects of HA molecular weight in the 
treatment of OA.
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